Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2012

01-06-2012 | NON-THEMATIC REVIEW

Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration

Authors: C. Wilmanns, S. Steinhauer, J. Großmann, A. Schmitt-Gräff, G. Ruf

Published in: Cancer and Metastasis Reviews | Issue 1-2/2012

Login to get access

Abstract

Cancer metastasis results from positive and negative cellular events such as constitutive activation of oncogenes (cOA) or genetic losses (GL) being modulated by downstream signals of epithelial–mesenchymal or mesenchymal–epithelial transition, thus constituting master programs of metastatic phenotype and site specificity. To address the complex nature of these programs, we introduced clinical and phenotypic markers like tumor size, grade, cellular shape, or expression of E-cadherin in 27 colon cancer (CC) patients (cOA and GL), and 41 patients with gastrointestinal stromal tumors (GIST, cOA) to produce scores of cOA and GL. Scores of cOA were highest in case of hepatic and lower in case of an isolated peritoneal spread (GIST), or (CC) of both, cOA and GL, highest in case of a combined hepatic and peritoneal spread and lower in case of an isolated peritoneal spread; but in case of an isolated hepatic spread, scores of cOA were high and low of GL. This indicates a differential contribution of cellular dissociation and recognition in site-specific metastasis, of cOA predominantly in production of hepatic and in the case of GL of serosal spread.
Literature
1.
2.
Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759–767.PubMedCrossRef
3.
Fidler, I. J., & Kripke, M. L. (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197, 893–895.PubMedCrossRef
4.
Fidler, I. J., & Poste, G. (2008). The “seed and soil” hypothesis revisited. The Lancet Oncology, 9, 808.PubMedCrossRef
5.
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nature Genetics, 33, 49–54.PubMedCrossRef
6.
Landemaine, T., Jackson, A., Bellahcène, A., Rucci, N., Sin, S., Abad, B. M., et al. (2008). A six-gene signature predicting breast cancer lung metastasis. Cancer Research, 68, 6092–6099.PubMedCrossRef
7.
Staroselsky, A. H., Pathak, S., Chernajovsky, Y., Tucker, S. L., & Fidler, I. J. (1991). Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma. Cancer Research, 51, 6292–6298.PubMed
8.
Tischoff, I., & Tannapfel, A. (2007). Pathologic and anatomic evidence of peritoneal metastases. Chirurg, 78, 1085–1090.PubMedCrossRef
9.
Finkelstein, S. D., Sayegh, R., Christensen, S., & Swalsky, P. A. (1993). Genotypic classification of colorectal adenocarcinoma. Cancer, 71, 3827–3838.PubMedCrossRef
10.
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., et al. (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. PNAS, 107, 246–251.PubMedCrossRef
11.
Lee, K. E., Lee, H.-J., Kim, Y. H., Yu, H. J., Yang, H.-K., Kim, W.-H., et al. (2003). Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Japanese Journal of Clinical Oncology, 33, 173–179.PubMedCrossRef
12.
Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., et al. (1998). E-cadherin germline mutations in familial gastric cancer. Nature, 392, 402–405.PubMedCrossRef
13.
Richards, F. M., McKee, S. A., Rajpar, M. H., Cole, T. R., Evans, D. G., Jankowski, J. A., et al. (1999). Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Human Molecular Genetics, 8, 607–610.PubMedCrossRef
14.
Sadahiro, S., Suzuki, T., Maeda, Y., Tanaka, A., Makuuchi, H., Kamijo, A., et al. (2009). Prognostic factors in patients with synchronous peritoneal carcinomatosis (PC) caused by a primary cancer of the colon. Journal of Gastrointestinal Surgery, 13, 1593–1598.PubMedCrossRef
15.
Kowalski, P. J., Rubin, M. A., & Kleer, C. G. (2003). E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Research, 5, R217–R222.PubMedCrossRef
16.
Moll, R., Mitze, M., Frixen, U. H., & Birchmeier, W. (1993). Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. American Journal of Pathology, 143, 1731–1742.PubMed
17.
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., et al. (2008). Wild-type Kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26, 1626–1634.PubMedCrossRef
18.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A., Lux, M. L., Ruiz, R., et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research, 61, 8118–8121.PubMed
19.
Wu, M., Pastor-Pareja, J. C., & Xu, T. (2010). Interaction between Ras V12 and scribbled clones induces tumour growth and invasion. Nature, 463, 545–548.PubMedCrossRef
20.
Eder, M. (1984). Metastasis, facts and problems in human pathology. Verhandlungen der Deutschen Gesellschaft für Pathologie, 68, 1–11.
21.
Acs, G., Lawton, T. J., Rebbeck, T. R., LiVolsi, V. A., & Zhang, P. J. (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. American Journal of Clinical Pathology, 115, 85–98.PubMedCrossRef
22.
Singer, S., Rubin, B. P., Lux, M. L., Chen, C.-J., Demetri, G. D., Fletcher, C. D. M., et al. (2002). Prognostic value of kit mutation type, mitotic activity, and histologic subtype in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 20, 3898–3905.PubMedCrossRef
23.
Wilmanns, C., Eggstein, S., & Ruf, G. (2007). Score prediction of metastatic risk in gastrointestinal stromal tumours (GIST). Zentralblatt für Chirurgie, 132, 509–514.PubMedCrossRef
24.
Wilmanns, C., Steinhauer, S., Grossmann, J., & Ruf, G. (2009). Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer. International Journal of Biological Sciences, 5, 458–465.PubMedCrossRef
25.
Nordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjeme, K., Bachallier, P., et al. (1996). Surgical resection of colorectal carcinoma metastases to the liver. Cancer, 77, 1254–1262.PubMedCrossRef
26.
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Annals of Surgery, 230, 309–321.PubMedCrossRef
27.
Lennon, A. M., Mulcahy, H. E., Hyland, J. M. P., Lowry, C., White, A., Fennelly, D., et al. (2003). Peritoneal involvement in stage II colon cancer. American Journal of Clinical Pathology, 119, 108–113.PubMedCrossRef
28.
Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Research, 60, 6750–6756.PubMed
29.
Jou, T.-S., & Nelson, W. J. (1998). Effects of regulated expression of mutant rhoA and rac1 small GTPases on the development of epithelial (MDCK) cell polarity. The Journal of Cell Biology, 142, 85–100.PubMedCrossRef
30.
Christofori, G., & Semb, H. (1999). The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends in Biochemical Sciences, 24, 73–76.PubMedCrossRef
31.
Franquemont, D. W. (1995). Differentiation and risk assessment of gastrointestinal stromal tumors. American Journal of Clinical Pathology, 103, 41–47.PubMed
32.
Carro, M. S., Lim, W. K., Alvarez, M. J., Bollo, R. J., Zhao, X., Snyder, E. Y., et al. (2010). The transcriptional network for mesenchymal transformation of brain tumours. Nature, 463, 318–325.PubMedCrossRef
33.
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314, 268–274.PubMedCrossRef
34.
Pratt, C. H., Vadigepalli, R., Chakravarthula, P., Gonye, G. E., Philp, N. J., & Grunwald, G. B. (2008). Transcriptional regulatory network analysis during epithelial-mesenchymal transformation of retinal pigment epithelium. Molecular Vision, 14, 1414–1428.PubMed
35.
Baugher, P. J., Krishnamoorthy, L., Price, J. E., & Dharmawardhane, S. F. (2005). Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Research, 7, R965–R974.PubMedCrossRef
36.
37.
Smith, K. J., Levy, D. B., Maupin, P., Pollard, T. D., Vogelstein, B., & Kinzler, K. W. (1994). Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Research, 54, 3672–3675.PubMed
38.
Munemitsu, S., Souza, B., Müller, O., Albert, I., Rubinfeld, B., & Polakis, P. (1994). The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Research, 54, 3676–3681.PubMed
39.
Safina, A. F., Varga, A. E., Bianchi, A., Zheng, Q., Kunnev, D., Liang, P., et al. (2009). Ras alters epithelial–mesenchymal transition in response to TGFβ by reducing actin fibers and cell-matrix adhesion. Cell Cycle, 8, 284–298.PubMedCrossRef
40.
Scaltriti, M., & Baselga, J. (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clinical Cancer Research, 12, 5268–5272.PubMedCrossRef
41.
August, D. A., Ottow, R. T., & Sugerbaker, P. H. (1984). Clinical perspective of human colorectal cancer metastasis. Cancer and Metastasis Reviews, 3, 303–324.PubMedCrossRef
42.
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., et al. (2009). PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 27, 2622–2629.PubMedCrossRef
43.
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217–221.PubMedCrossRef
44.
Anthony, T., George, R., Rodriguez-Bigas, M., & Petrelli, N. J. (1996). Primary signet-ring cell carcinoma of the colon and rectum. Annals of Surgical Oncology, 3, 344–348.PubMedCrossRef
45.
Kern, S. E., Fearon, E. R., Tersmette, K. W. F., Enterline, J. P., Leppert, M., Nakamura, Y., et al. (1989). Allelic loss in colorectal carcinoma. Journal of the American Medical Association, 261, 3099–3103.PubMedCrossRef
46.
Goi, T., Yamaguchi, A., Nakagawara, G., Urano, T., Shiku, H., & Furukawa, K. (1998). Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. British Journal of Cancer, 77, 466–471.PubMedCrossRef
47.
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949–954.PubMedCrossRef
48.
Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Cambacorta, M., et al. (2008). Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology, 26, 4217–4219.PubMedCrossRef
49.
Grille, S. J., Bellacosa, A., Upson, J., Klein-Szanto, A. J., van Roy, F., Lee-Kwon, W., et al. (2003). The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Research, 63, 2172–2178.PubMed
50.
Zeisberg, M., Shah, A. A., & Kalluri, R. (2005). Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. Journal of Biological Chemistry, 280, 8094–8100.PubMedCrossRef
51.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., et al. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 7, 561–573.PubMedCrossRef
52.
Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., et al. (2009). PIK3CA mutation is associated with poor prognosis among patiens with curatively resected colon cancer. Journal of Clinical Oncology, 27, 1477–1484.PubMedCrossRef
53.
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research, 69, 4286–4293.PubMedCrossRef
54.
Sanders, K. M., & Ward, S. M. (2006). Interstitial cells of Cajal: a new perspective on smooth muscle function. Journal of Physiology, 576, 721–726.PubMedCrossRef
55.
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., et al. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology, 33, 459–465.PubMedCrossRef
56.
Yarden, Y., Escobedo, J. A., Kuang, W.-J., Yang-Feng, T. L., Daniel, T. O., Tremble, P. M., et al. (1986). Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature, 323, 226–232.PubMedCrossRef
57.
DeMatteo, R. P., Heinrich, M. C., El-Rifai, W. M., & Demetri, G. (2002). Clinical management of gastrointestinal stromal tumors: before and after STI-571. Human Pathology, 33, 466–477.PubMedCrossRef
58.
Sattler, M., Salgia, R., Shrikhande, G., Verma, S., Pisick, E., Prasad, K. V. S., et al. (1997). Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120CBL. Journal of Biological Chemistry, 272, 10248–10253.PubMedCrossRef
59.
Yang, J., Du, X., Lazar, A. J. F., Pollock, R., Hunt, K., Chen, K., et al. (2008). Genetic aberrations of gastrointestinal stromal tumors. Cancer, 113, 1532–1543.PubMedCrossRef
60.
Agaimy, A., Pelz, A.-F., Corless, C. L., Wünsch, P. H., Heinrich, M. C., Hofstaedter, F., et al. (2007). Epitheloid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. Oncology Reports, 18, 9–15.PubMed
61.
Sakamoto, K., Sakurai, S., Kanda, T., Sakuma, Y., Hishima, T., Hironaka, M., et al. (2010). Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment. Cancer Science, 101, 1270–1278.PubMedCrossRef
62.
Shimoyama, Y., Hirohashi, S., Hirano, S., Noguchi, M., Shimosato, Y., Takeichi, M., et al. (1989). Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Research, 49, 2128–2133.PubMed
63.
Berndorff, D., Gessner, R., Kreft, B., Schnoy, N., Lajous-Petter, A.-M., Loch, N., et al. (1994). Liver-intestine cadherin: molecular cloning and characterization of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. The Journal of Cell Biology, 125, 1353–1369.PubMedCrossRef
64.
Becker, K.-F., Atkinson, M. J., Reich, U., Becker, I., Nekarda, H., Siewert, J. R., et al. (1994). E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Research, 54, 3845–3852.PubMed
65.
Tamura, G., Yin, J., Wang, S., Fleisher, A. S., Zou, T., Abraham, J. M., et al. (2000). E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. Journal of the National Cancer Institute, 92, 569–573.PubMedCrossRef
66.
Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., et al. (1993). E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Research, 53, 1690–1695.PubMed
67.
Steeg, P. S., Horak, C. E., & Miller, K. D. (2008). Clinical-translational approaches to the nm23-H1 metastasis suppressor. Clinical Cancer Research, 14, 5006–5012.PubMedCrossRef
68.
Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004). Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature, 430, 1034–1040.PubMedCrossRef
69.
Yu, Y., Zhang, S., Wang, X., Yang, Z., & Ou, G. (2010). Overexpression of TrkB promotes the progression of colon cancer. APMIS, 118, 188–195.PubMedCrossRef
70.
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial–mesenchymal transition. The Journal of Clinical Investigation, 119, 1420–1428.PubMedCrossRef
71.
Bissell, M. J., Radisky, D. C., Rizki, A., Weaver, V. M., & Peterson, O. W. (2002). The organizing principle: microenvironmental influences in the normal and malignang breast. Differentiation, 70, 537–546.PubMedCrossRef
Metadata
Title
Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration
Authors
C. Wilmanns
S. Steinhauer
J. Großmann
A. Schmitt-Gräff
G. Ruf
Publication date
01-06-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9350-3

Other articles of this Issue 1-2/2012

Cancer and Metastasis Reviews 1-2/2012 Go to the issue

NON-THEMATIC REVIEW

The Eph/Ephrin family in cancer metastasis: communication at the service of invasion

NON-THEMATIC REVIEW

A new hypothesis for the cancer mechanism

NON-THEMATIC REVIEW

Potential roles for prions and protein-only inheritance in cancer

NON-THEMATIC REVIEW

S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence

NON-THEMATIC REVIEW

Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression

NON-THEMATIC REVIEW

In vivo animal models of spinal metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits